Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

302 Views

Poster Session: Clinical Trials

217 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Lipopeptide QPX9003 in Healthy Adult Subjects

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Co-Author(s)

DG

David Griffith, n/a

Sr. Vice-President, Non-Clinical and Clinical Development
Qpex Biopharma
San Diego, California, United States

Presenting Author(s)

Yehuda Carmeli, MD

Professor of Medicine, Head of the Israeli National Center for Antibiotic Resistance, Chief of the Division of Epidemiology
Israel Ministry of Health
Tel Aviv, Tel Aviv, Israel

Co-Author(s)

SG

Shawnee Gehrke, n/a

Clinical Research Associate
Qpex Biopharma
San Diego, California, United States
EM

Elizabeth Morgan, n/a

Sr. Vice-President, Clinical and Regulatory Operations
Qpex Biopharma
San Diego, California, United States
MD

Michael Dudley, n/a

CEO
Qpex Biopharma
San Diego, California, United States
Jeff Loutit, MBChB

Chief Medical Officer
Qpex Biopharma
San Diego, California, United States